PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 22, 2019Circulation278 citationsOpen Access

Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects

View Full Paper
MSMotoaki SanoSGShinichi Goto

Key Points

  • This review examines how SGLT2 inhibitors raise levels of erythropoietin, hemoglobin, and hematocrit in type 2 diabetes patients.
  • Literature review on the effects of SGLT2 inhibitors on hematocrit levels
  • Analysis of the implications for chronic kidney disease progression and heart failure
  • Exploration of mortality rates linked to SGLT2 inhibitor use
  • Elevation of erythropoietin and hematocrit linked to SGLT2 inhibitor treatment
  • Reduction in chronic kidney disease progression and lower heart failure hospitalization
  • Lower mortality rates associated with the use of SGLT2 inhibitors in type 2 diabetes patients

Abstract

his review focuses on the postulated mechanism underlying elevation of erythropoietin, hemoglobin, and hematocrit levels in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 (SGLT2) inhibitors and how this phenomenon is linked to reduced progression of chronic kidney disease, lower mortality, and a lower risk of heart failure hospitalization.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sano et al. (2019) studied this question.

synapsesocial.com/papers/69deac02077ec87fd1e93e5dhttps://doi.org/10.1161/circulationaha.118.038881
Ask AI
Helpful
Bookmark
Share
View Full Paper